# metabolic dysfunction-associated steatohepatitis (MASH) - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: DISEASE-STATE
- Tissue / sample source: liver tissue
- Comparison or endpoint: MASH/NASH versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: f634f84e95c290ce4195eb13604b114b4c86ce8adb76238e59c436c955ac43b9
- Response HTTP status: 200
- Prompt tokens: 40405
- Completion tokens: 15239
- Reasoning tokens: 0
- Total tokens: 55644
- API requests reported: 3
- Elapsed seconds: 82.392
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1019.869
- Question handoff seconds: 1032.938
- Final benchmark system: E2seq; file rank 4/5; original repeat 5; model vendor: DeepSeek

---
# Multidimensional Interpretation of MASH/NASH versus Healthy Liver Transcriptomic Data

## 1. Overall Biological Interpretation

The dataset (100 unique genes, 51 upregulated, 49 downregulated, all FDR ≤ 0.01) reveals a transcriptomic landscape in MASH/NASH liver tissue characterized by several dominant themes.

The most striking feature is a **strong upregulation of innate immune and inflammatory programs**, anchored by TREM2 (log2FC = 4.91), UBD (log2FC = 4.15), CXCL10 (log2FC = 3.46), and TNFRSF12A (log2FC = 3.27). This is accompanied by a **concurrent downregulation of a broad set of macrophage scavenger/clearance receptors** including CD163 (log2FC = −2.52), MARCO (log2FC = −2.84), MRC1 (log2FC = −2.10), CD5L (log2FC = −2.90), and TIMD4 (log2FC = −4.28). This bidirectional pattern suggests a shift in the hepatic macrophage compartment—away from "restorative"/scavenging phenotypes and toward inflammatory/activated states—rather than a simple global immune activation.

A second major theme is **mitochondrial and metabolic stress**: multiple mitochondrial tRNA genes (TRNK, TRNS1, TRNC, TRNL2, TRNY) are strongly upregulated alongside CYCS (log2FC = 1.56), TIMM17A (log2FC = 1.28), and MTHFD1L (log2FC = 1.72), while CBS (log2FC = −1.25) and SCLY (log2FC = −1.28) are downregulated. This pattern is consistent with mitochondrial dysfunction, oxidative stress, and altered one-carbon/sulfur metabolism.

A third theme is **loss of sinusoidal endothelial and vascular identity**: LYVE1 (log2FC = −2.73), CDH5 (log2FC = −1.38), and VCAM1 (log2FC = −2.38) are all downregulated, suggesting capillarization or dedifferentiation of liver sinusoidal endothelial cells, a well-recognized feature of progressive MASH.

A fourth theme involves **ribosomal and translational upregulation** (RPL9, RPSA2, PFDN6, MTRNR2L8), which may reflect hepatocyte regenerative stress or a general anabolic response.

Finally, a substantial fraction of the most significant genes are **non-coding RNAs and pseudogenes** (UQCRBP1, CD81-AS1, SNORD140, LOC105377700, MIR4647, MIR12136, MIR4426, MIR1244-1, MIR1825, MIR4721, MIR6717, DIO3OS, LINC01485, MRPL1-AS1, multiple LOC identifiers). This should be flagged as a potential technical artifact (see Limitations), though some may have genuine regulatory roles.

---

## 2. Core Biological Programs

### Program 1: Inflammatory Macrophage Activation and Innate Immune Response
- **Direction**: Upregulated (TREM2, CXCL10, UBD, TNFRSF12A, CAPG), with concurrent downregulation of scavenger receptors (CD163, MARCO, MRC1, CD5L, TIMD4, FOLR2)
- **Supporting genes**: TREM2 (log2FC = 4.91), UBD (log2FC = 4.15), CXCL10 (log2FC = 3.46), TNFRSF12A (log2FC = 3.27), CAPG (log2FC = 2.57), CD163 (log2FC = −2.52), MARCO (log2FC = −2.84), MRC1 (log2FC = −2.10), CD5L (log2FC = −2.90), TIMD4 (log2FC = −4.28)
- **Pathway**: Hallmark "Inflammatory Response"; GO "Innate Immune Response" (GO:0045087); Reactome "Signaling by CSF1 (M-CSF) in myeloid cells"
- **Explanation**: The coordinated upregulation of TREM2 (a key marker of disease-associated macrophages in MASH) with the chemokine CXCL10 and the stress-inducible ubiquitin-like protein UBD, together with downregulation of classical restorative macrophage markers (CD163, MRC1, MARCO, TIMD4, CD5L), collectively indicates a phenotypic switch in the hepatic macrophage compartment toward an inflammatory, lipid-associated state. The CSF1R/TREM2 network connection retrieved from OmniPath supports a coordinated myeloid differentiation program.
- **Evidence strength**: Strong for the differential expression itself (all FDR < 1.2e-7). The interpretation as a "macrophage phenotype switch" is a supported hypothesis based on the known biology of these markers, but direct cell-type-resolved evidence is not provided by the current dataset. External literature on TREM2+ macrophages in MASH supports this interpretation.

### Program 2: Mitochondrial Stress and Metabolic Reprogramming
- **Direction**: Upregulated (mitochondrial tRNAs, CYCS, TIMM17A, MTHFD1L, MANF), downregulated (CBS, SCLY)
- **Supporting genes**: TRNK (log2FC = 2.73), TRNS1 (log2FC = 3.05), TRNC (log2FC = 4.07), TRNL2 (log2FC = 3.86), TRNY (log2FC = 3.57), CYCS (log2FC = 1.56), TIMM17A (log2FC = 1.28), MTHFD1L (log2FC = 1.72), CBS (log2FC = −1.25), SCLY (log2FC = −1.28), MANF (log2FC = 1.85)
- **Pathway**: KEGG "Aminoacyl-tRNA biosynthesis"; GO "Mitochondrial Translation"; Reactome "Mitochondrial import"
- **Explanation**: The coordinated upregulation of multiple mitochondrial tRNA genes and TIMM17A (a TIM23 complex component) suggests increased mitochondrial import/translation activity, potentially as a compensatory response to mitochondrial dysfunction. CYCS upregulation is consistent with mitochondrial stress signaling. The downregulation of CBS (cystathionine beta-synthase) and SCLY (selenocysteine lyase) points to disruption of transsulfuration and one-carbon metabolism—pathways central to hepatic redox homeostasis. MTHFD1L upregulation further implicates altered folate/one-carbon metabolism.
- **Evidence strength**: Moderate. The differential expression is highly significant, but the biological interpretation as "mitochondrial dysfunction" is inferential. The KEGG "Aminoacyl-tRNA biosynthesis" enrichment from the batch analysis is consistent with the tRNA upregulation but does not constitute an independent statistical test from this dataset. The mitochondrial tRNA upregulation may also represent a technical artifact (see Limitations).

### Program 3: Loss of Sinusoidal Endothelial Identity and Vascular Remodeling
- **Direction**: Downregulated
- **Supporting genes**: LYVE1 (log2FC = −2.73), CDH5 (log2FC = −1.38), VCAM1 (log2FC = −2.38), CD209 (log2FC = −2.43), STAB1 (not present but related), PCDH20 (log2FC = −4.59)
- **Pathway**: GO "Cell-Cell Adhesion Via Plasma-Membrane Adhesion Molecules" (GO:0098742); Reactome "Cell junction organization"
- **Explanation**: LYVE1 is a canonical marker of healthy liver sinusoidal endothelial cells (LSECs). Its downregulation, alongside CDH5 (VE-cadherin) and the endothelial adhesion molecule VCAM1, indicates LSEC dedifferentiation/capillarization—a hallmark of progressive MASH that precedes and promotes hepatocyte injury and fibrosis. CD209 (DC-SIGN) is also expressed on LSECs and hepatic dendritic cells; its loss is consistent with this phenotype.
- **Evidence strength**: Moderate-strong. The direction and gene identities are consistent with well-established MASH pathology. However, since this is bulk liver tissue, the cell-type attribution is inferential. The GO term "Cell-Cell Adhesion Via Plasma-Membrane Adhesion Molecules" was retrieved in the batch analysis but is not a formal enrichment statistic from this dataset.

### Program 4: Ribosomal Biogenesis and Translational Upregulation
- **Direction**: Upregulated
- **Supporting genes**: RPL9 (log2FC = 1.47), RPSA2 (log2FC = 1.22), PFDN6 (log2FC = 1.49), MTRNR2L8 (log2FC = 3.25), FABP5 (log2FC = 2.85)
- **Pathway**: GO "Cytoplasmic Translation"; KEGG "Ribosome"
- **Explanation**: The upregulation of ribosomal proteins (RPL9, RPSA2) and the chaperone PFDN6 (prefoldin subunit 6, involved in folding of actin/tubulin but also ribosomal assembly) suggests increased translational capacity. This may reflect hepatocyte regenerative stress, or the expansion of cells with high biosynthetic demand. FABP5 upregulation is consistent with altered lipid trafficking.
- **Evidence strength**: Weak-moderate. The individual genes are significant, but the program is supported by few genes and may be a secondary effect of the immune cell expansion or a technical artifact of RNA composition changes. This program should be considered exploratory.

### Program 5: Complement and Scavenging Receptor Downregulation
- **Direction**: Downregulated
- **Supporting genes**: CR1 (log2FC = −3.61), CFP (log2FC = −1.86), CD163 (log2FC = −2.52), MARCO (log2FC = −2.84), MRC1 (log2FC = −2.10), CD5L (log2FC = −2.90), TIMD4 (log2FC = −4.28)
- **Pathway**: GO "Regulation of Complement Activation, Classical Pathway" (GO:0030450); KEGG "Tuberculosis" (phagosome pathway); Reactome "Complement cascade"
- **Explanation**: The coordinated downregulation of complement receptors (CR1) and regulators (CFP, properdin), together with multiple scavenger receptors (CD163, MARCO, MRC1, CD5L, TIMD4), suggests suppression of the clearance/efferocytosis arm of the innate immune system. This is consistent with impaired clearance of dead cells and debris—a known contributor to MASH progression. The STRING network records linking CFP-CR1 and CD163-MRC1-SIGLEC1 support pathway co-membership.
- **Evidence strength**: Moderate. The pattern is coherent and biologically plausible. However, the retrieved GO term "Regulation of Complement Activation, Classical Pathway" from the batch analysis is not a formal enrichment statistic from this dataset. External literature on efferocytosis-related biomarkers in MASH (PMID 39497821) supports the relevance of this program.

---

## 3. Key Genes and Interaction Modules

### 1. TREM2 (upregulated, log2FC = 4.91, FDR = 3.9e-9)
- **Role**: Central marker of disease-associated macrophages (DAMs) / lipid-associated macrophages in MASH. Its strong upregulation is the single most striking immune signal in this dataset.
- **Relationship to other genes**: TREM2 and CSF1R are linked via OmniPath regulatory records (CSF1R regulates TREM2+ macrophage differentiation); CSF1R is downregulated (log2FC = −1.98), which may represent a compensatory or divergent signal. This is a **regulatory relationship** (CSF1R → macrophage differentiation → TREM2 expression), not evidence of direct physical interaction.
- **Evidence**: Direct (differential expression); disease-association (TREM2+ macrophages are established in MASH literature); pathway (Reactome "Signaling by CSF1 in myeloid cells").

### 2. CD163 / MRC1 / MARCO / TIMD4 / CD5L / FOLR2 module (all downregulated)
- **Role**: This module represents the coordinated loss of restorative/scavenging macrophage markers. The STRING records show CD163-MRC1 and CD163-SIGLEC1 edges (pathway co-membership / predicted interactions, not direct physical binding).
- **Relationship type**: **Co-expression / pathway co-membership**; these genes are co-regulated markers of the same macrophage subpopulation. They are not known to physically interact with each other.
- **Evidence**: Direct (differential expression); expression/tissue (these are well-established macrophage markers); literature (efferocytosis-related biomarkers in MASH, PMID 39497821).

### 3. UBD (upregulated, log2FC = 4.15, FDR = 1.3e-10)
- **Role**: Ubiquitin D (also called FAT10), a stress-inducible ubiquitin-like modifier involved in NF-κB signaling and apoptosis. Its upregulation is consistent with inflammatory and proteotoxic stress in MASH hepatocytes and immune cells.
- **Relationship**: No direct interaction evidence in the current dataset; likely **pathway co-membership** with the inflammatory program.
- **Evidence**: Direct; literature (UBD is induced by TNF/IFN and is a marker of inflammatory stress).

### 4. CXCL10 (upregulated, log2FC = 3.46, FDR = 1.2e-7)
- **Role**: Chemokine recruiting T cells and NK cells; a canonical IFN-γ-responsive gene. Its upregulation indicates an active interferon-driven inflammatory circuit.
- **Relationship**: CXCL10 is downstream of IFN-γ signaling; UBD is also IFN/TNF-inducible. These are **pathway co-members** in the inflammatory program, not direct interactors.
- **Evidence**: Direct; pathway (chemokine signaling); literature (CXCL10 is elevated in NASH).

### 5. Mitochondrial tRNA cluster (TRNK, TRNS1, TRNC, TRNL2, TRNY; all strongly upregulated)
- **Role**: Five mitochondrial tRNAs are among the most strongly upregulated genes. This may indicate mitochondrial biogenesis/translation stress, or a technical artifact (mitochondrial RNA contamination or composition effects).
- **Relationship**: These genes are **co-regulated** as part of the mitochondrial genome transcript; they do not interact as proteins.
- **Evidence**: Direct; KEGG "Aminoacyl-tRNA biosynthesis" in the batch analysis; however, the biological interpretation is uncertain.

### 6. LYVE1 (downregulated, log2FC = −2.73, FDR = 5.2e-9)
- **Role**: Canonical LSEC marker; its loss indicates sinusoidal capillarization. This is a critical early event in MASH progression.
- **Relationship**: LYVE1 loss is coordinated with CDH5 and VCAM1 downregulation (endothelial program). These are **co-expressed** in LSECs; no direct physical interaction is implied.
- **Evidence**: Direct; expression/tissue (LSEC specificity); literature (LSEC capillarization in MASH).

### 7. FOXM1 (upregulated, log2FC = 2.14, FDR = 4.2e-7)
- **Role**: Proliferation-associated transcription factor. Its upregulation may reflect hepatocyte regenerative proliferation or expansion of progenitor-like cells. STRING records link FOXM1 with CDH5 and TCF7L1 via CTNNB1 (β-catenin) as an intermediary.
- **Relationship**: FOXM1, CDH5, and TCF7L1 are connected through CTNNB1 in STRING—this is a **pathway co-membership** (Wnt/β-catenin signaling), not evidence of direct physical interaction among all three.
- **Evidence**: Direct; pathway (cell cycle, Wnt signaling); literature (FOXM1 in liver regeneration and HCC).

### 8. CAST (upregulated, log2FC = 4.02, FDR = 7.0e-8; note: flagged as "direction-conflict; rows=2")
- **Role**: Calpastatin, the endogenous inhibitor of calpains. Its upregulation may be protective against calpain-mediated injury, or may reflect a specific cell population.
- **Caution**: The ledger flags this gene as having 2 rows with direction conflict. The displayed log2FC is positive, but the duplicate row may have opposite direction. This gene should be interpreted with caution.
- **Relationship**: Indirect/putative in the context of proteotoxic stress.
- **Evidence**: Direct (with the direction-conflict caveat).

### 9. MANF (upregulated, log2FC = 1.85, FDR = 6.1e-7)
- **Role**: Mesencephalic astrocyte-derived neurotrophic factor; an ER-stress-responsive cytoprotective factor. Its upregulation is consistent with ER stress in MASH. STRING records link MANF to CD5L and HSPA5 (BiP/GRP78).
- **Relationship**: MANF-HSPA5 is a **regulatory interaction** (MANF binds to and modulates the ER stress sensor). MANF-CD5L connection is likely **indirect/putative**.
- **Evidence**: Direct; pathway (unfolded protein response); literature (MANF in ER stress and metabolic disease).

### 10. CETP (downregulated, log2FC = −2.49, FDR = 2.0e-8)
- **Role**: Cholesteryl ester transfer protein; primarily expressed in the liver. Its downregulation may reflect altered lipid metabolism or reduced hepatocyte mass/function.
- **Relationship**: Indirect/putative within the metabolic program.
- **Evidence**: Direct; literature (CETP and HDL metabolism in NAFLD).

---

## 4. Validation Priorities

### Priority 1: Cell-Type-Resolved Validation of the Macrophage Phenotype Switch
- **Classification**: Confounding or composition check / Mechanistic hypothesis
- **Why**: The TREM2-up/CD163-down pattern is the most striking finding, but bulk RNA-seq cannot distinguish whether this reflects a true phenotypic switch within a stable macrophage population or a compositional shift (e.g., recruitment of TREM2+ monocytes replacing resident CD163+ Kupffer cells).
- **Current evidence**: Differential expression of TREM2 (up) and CD163/MRC1/MARCO/TIMD4/CD5L (down) in bulk liver tissue.
- **External evidence**: TREM2+ lipid-associated macrophages are established in MASH (mouse and human studies); CD163+ Kupffer cells are known to be depleted in advanced NASH. Literature supports both interpretations (phenotype switch and composition change).
- **Next step**: Single-cell or single-nucleus RNA-seq / multiplex immunofluorescence on matched liver biopsies to quantify macrophage subsets directly.
- **Conclusion status**: **Supported hypothesis** (the differential expression is established; the cell-type interpretation requires validation).

### Priority 2: Functional Validation of TREM2 as a Therapeutic Target
- **Classification**: Therapeutic target
- **Why**: TREM2+ macrophages are consistently implicated in MASH progression across species and studies; TREM2 is druggable (antibodies and small molecules in development).
- **Current evidence**: Strong upregulation in this dataset (log2FC = 4.91, FDR = 3.9e-9).
- **External evidence**: Preclinical studies show TREM2 deletion worsens or ameliorates steatohepatitis depending on context; anti-TREM2 antibodies are in clinical development for other indications. The direction of therapeutic benefit (agonist vs. antagonist) remains debated.
- **Next step**: Preclinical loss- and gain-of-function studies in MASH models, followed by careful evaluation of macrophage polarization and fibrosis endpoints. Note: the existence of drug development programs does not constitute evidence of efficacy in MASH.
- **Conclusion status**: **Exploratory hypothesis** (the association is established; the therapeutic direction is not).

### Priority 3: Validation of LSEC Capillarization as an Early Biomarker
- **Classification**: Biomarker
- **Why**: LYVE1 downregulation is a sensitive indicator of LSEC dedifferentiation, which precedes fibrosis. Circulating markers of LSEC injury could serve as non-invasive biomarkers.
- **Current evidence**: LYVE1 (log2FC = −2.73), CDH5 (log2FC = −1.38), VCAM1 (log2FC = −2.38) all downregulated.
- **External evidence**: LSEC capillarization is a well-established feature of progressive MASH; VCAM1 is a known soluble marker of endothelial activation.
- **Next step**: Measure soluble LYVE1 or VCAM1 in serum/plasma of MASH patients across fibrosis stages; correlate with biopsy-proven LSEC phenotype.
- **Conclusion status**: **Supported hypothesis** for the tissue-level finding; **exploratory** for the circulating biomarker claim.

### Priority 4: Investigation of Mitochondrial tRNA Upregulation
- **Classification**: Confounding or composition check / Mechanistic hypothesis
- **Why**: The strong upregulation of five mitochondrial tRNAs is unusual and could reflect either genuine mitochondrial stress or a technical artifact (e.g., differential RNA extraction efficiency, mitochondrial contamination, or cell-composition effects).
- **Current evidence**: TRNK (2.73), TRNS1 (3.05), TRNC (4.07), TRNL2 (3.86), TRNY (3.57) all strongly upregulated.
- **External evidence**: Mitochondrial dysfunction is established in NASH; however, mitochondrial tRNA upregulation is not a standard reported feature.
- **Next step**: qPCR validation with mitochondrial/nuclear DNA normalization; assessment of mitochondrial mass by flow cytometry or histology; RNA integrity metrics to rule out degradation artifacts.
- **Conclusion status**: **Exploratory hypothesis**; requires technical validation before biological interpretation.

### Priority 5: Independent Cohort Replication and Meta-Analysis
- **Classification**: Interaction / network hypothesis (replication)
- **Why**: All conclusions currently rest on a single cohort. External statistical validation was not performed.
- **Current evidence**: 100 genes with FDR ≤ 0.01 in the current dataset.
- **External evidence**: Published MASH transcriptomic datasets exist (e.g., GSE126848, GSE135251, GSE130970), but no independent-cohort statistic has been computed here.
- **Next step**: Test the direction and significance of the top genes (especially TREM2, CD163, LYVE1, UBD, CXCL10) in at least two independent MASH liver transcriptomic cohorts; perform meta-analysis.
- **Conclusion status**: **Established evidence** for the current cohort; **not yet validated** externally.

---

## 5. Evidence Grounding Summary

| Claim | Direct (this dataset) | Pathway/Ontology | Interaction/Regulatory | Disease/Literature | Independence notes |
|---|---|---|---|---|---|
| TREM2 upregulation | Yes (log2FC = 4.91, FDR = 3.9e-9) | Reactome CSF1 signaling | CSF1R-TREM2 (OmniPath, regulatory) | Established in MASH literature | Partially overlapping: Reactome/OmniPath may share underlying literature |
| Macrophage phenotype switch | Yes (TREM2 up; CD163/MRC1/MARCO/TIMD4/CD5L down) | GO innate immunity | STRING CD163-MRC1-SIGLEC1 (co-membership) | Efferocytosis biomarkers in MASH (PMID 39497821) | STRING edges are predicted/curated; not direct physical interaction |
| LSEC capillarization | Yes (LYVE1, CDH5, VCAM1 down) | GO cell-cell adhesion | Not applicable | Well-established in NASH pathology | Independent evidence streams |
| Mitochondrial stress | Yes (tRNA cluster, CYCS, TIMM17A up) | KEGG aminoacyl-tRNA biosynthesis | Not applicable | Mitochondrial dysfunction in NASH | KEGG annotation is not an independent statistical test |
| FOXM1 proliferation program | Yes (log2FC = 2.14) | Cell cycle | STRING: FOXM1-CDH5-TCF7L1 via CTNNB1 (co-membership) | FOXM1 in liver regeneration | STRING connection is pathway-level, not physical |

**Important caveat on evidence independence**: The pathway/ontology annotations (GO, Reactome, KEGG), interaction records (STRING, OmniPath), and literature sources are not fully independent—they often derive from the same underlying publications or prediction models. The only genuinely independent evidence in this analysis is the uploaded differential expression statistics (direct evidence) and, separately, the external literature that was not used to generate those statistics.

---

## 6. Limitations and Alternative Explanations

### 1. Cell-Composition Effects (Most Important)
Bulk liver tissue RNA reflects the relative proportions of hepatocytes, Kupffer cells, infiltrating macrophages, LSECs, hepatic stellate cells, and other populations. The TREM2 upregulation and CD163 downregulation could reflect recruitment of monocyte-derived TREM2+ macrophages rather than a phenotypic switch in resident cells. Similarly, the apparent loss of LSEC markers may reflect reduced LSEC proportion in fibrotic tissue. **How to distinguish**: Single-cell RNA-seq, immunohistochemistry, or deconvolution algorithms (CIBERSORTx, BisqueRNA) applied to bulk data.

### 2. Non-Coding RNA and Pseudogene Signal
A substantial fraction of the top genes are non-coding RNAs (MIR4647, MIR12136, MIR4426, MIR1244-1, MIR1825, MIR4721, MIR6717, DIO3OS, LINC01485, CD81-AS1, MRPL1-AS1, NUCB1-AS1, HSPA9-AS1, MROH2B-DT) and pseudogenes (UQCRBP1, GLUD1P2, GUSBP2, CES1P2, LOC105377700, LOC107984754, LOC107986183, LOC107986158, LOC102724560, LOC105371873). While some may have genuine regulatory functions, this pattern raises the possibility of **alignment or annotation artifacts**, or of genuine but poorly understood transcriptional noise. **How to investigate**: Verify with independent alignment (e.g., STAR vs. HISAT2), check for multi-mapping reads, and validate key candidates by qPCR.

### 3. Mitochondrial tRNA Upregulation as Potential Artifact
The coordinated upregulation of five mitochondrial tRNAs is biologically unusual. Possible explanations include: (a) genuine mitochondrial stress response; (b) differential mitochondrial content between MASH and control livers (composition effect); (c) technical differences in RNA extraction or rRNA depletion efficiency. **How to distinguish**: Normalize to mitochondrial DNA copy number; assess mitochondrial mass by histology; check RNA quality metrics.

### 4. Disease Severity and Heterogeneity
The comparison is "MASH/NASH versus healthy control," but MASH spans a spectrum from mild to severe (F0-F4 fibrosis, NAS 1-8). Without stratification by fibrosis stage, inflammation grade, or steatosis grade, the observed signals may be driven predominantly by the most severe cases, or may be diluted by mild cases. **How to investigate**: Stratify by fibrosis stage and NAS score; perform stage-specific analyses.

### 5. Association Versus Causation and Lack of External Replication
All conclusions are based on a single cross-sectional comparison. The direction of causality (does the transcriptomic change drive disease, or is it a consequence of the diseased tissue state?) cannot be determined. External statistical validation in an independent cohort was **not performed**—pathway annotations and literature support are contextual, not replication. **How to address**: Independent cohort replication, longitudinal sampling, and functional perturbation experiments.

---

## Summary Statement

The current transcriptomic data from MASH versus healthy liver tissue provides strong direct evidence (100 genes, all FDR ≤ 0.01) for coordinated immune activation (TREM2 upregulation with concurrent loss of scavenger macrophage markers), LSEC dedifferentiation (LYVE1/CDH5/VCAM1 downregulation), and mitochondrial/metabolic stress (mitochondrial tRNA and one-carbon metabolism gene dysregulation), with the macrophage phenotype-shift interpretation being the most biologically coherent and literature-supported hypothesis, though it requires cell-type-resolved validation and independent cohort replication before any causal or therapeutic conclusions can be drawn.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=43, external claims checked=0, external mismatches=0, status=passed.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 93/100 selected items (records returned); cbioportal 85/100 selected items (records returned); chembl 33/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 82/100 selected items (records returned); ensembl 42/100 selected items (partially returned; some queries failed); europepmc 897 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 75/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 66/100 selected items (records returned); humanbase 91/100 selected items (records returned); intact 69/100 selected items (records returned); mygene 96/100 selected items (records returned); omnipath 40/100 selected items (records returned); opentargets 89/100 selected items (records returned); pubmed 612 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 69/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 69/100 selected items (records returned)
Local databases: gutmgene 1/100 selected items (records returned); hmdb 28/100 selected items (records returned); string 67/100 selected items (records returned); trrust 17/100 selected items (records returned)
